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Summary: Recently a striking elevation of the activity of chitotriosidase, anendo 
~glucosaminidase distinct from lysozyme, was found in plasma from patients with 
Gaucher type I disease (McKusick 230800). Plasma chitotriosidase originates from 
activated macrophages and this elevation is secondary to the basic defect in Gaucher 
disease. To investigate the specificity of this phenomenon, we have investigated 24 
different lysosomal storage diseases. In 11 different diseases increased chito- 
triosidase activity in plasma was found (in 28% of the patients). None of these 
diseases howed elevations as high as in Gaucher disease. Chitotriosidase was not 
significantly elevated in plasma from 20 different non-lysosomal enzymopathies or 
in plasma from patients with infectious diseases associated with hepatomegaly. The 
results how that marked elevation of chitotriosidase activity in plasma ppears to be 
specific for Gaucher disease. The data further suggest that elevated levels of chito- 
triosidase activity in plasma from patients with unexplained iseases may be 
indicative for a lysosomal disorder. 
Recently it was demonstrated that plasma of patients with Gaucher disease had 100-1000- 
fold elevated activity of chitotriosidase (Hollak et al 1994). Chitotriosidase is probably 
identical to a previously described chitotetraosidase, an endo fl-glucosaminidase distinct 
from lysozyme (Den Tandt et al 1988) which is secreted by activated macrophages (Hollak 
et al 1994). The elevation in Gaucher disease is secondary to the well established primary 
defect in this disease: a deficiency of the lysosomal hydrolase fl-glucosidase (for review 
see Beutler and Grabowski 1995). 
We were interested whether this novel marker for Gaucher disease would also be useful 
in detecting other (metabolic) disorders. Here we report elevated levels in 11 different 
lysosomal storage disorders. 
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MATERIALS AND METHODS 
Chitotriosidase activity was determined by incubating 5#1 plasma or serum with 100/.tl 
22#mol/L 4-methylumbelliferyl-l~-D-N,N',N"-triacetylchitotriose (MU-(I~-GlcNAc)3; 
Sigma) in Mcllvain's phosphate-citrate buffer, pH 5.2, for 1 h at 37~ (modified from 
Hollak et al 1994). Reactions were terminated by adding 120#1 0.5mol/L Na2CO 3- 
NaHCO 3 buffer, pH 10.7, and the fluorescence of 4-methylumbelliferone was read in a 
Fluoroskan fluorimeter (Titertek; excitation 355 nm, emission 460 nm). 
Chitotriosidase was also determined in leukocytes and cultured fibroblasts by substi- 
tuting plasma for sonicated homogenates containing 20/.tg protein. 
RESULTS 
Kinetic properties and origin of plasma chitotriosidase: The apparent K m for MU- 
chitotrioside could not be determined since chitotriosidase showed strong substrate 
inhibition at concentrations above 0.1 mmol/L. Maximal activity was obtained at a MU- 
(/3-GIcNAc) 3 concentration of 20/.tmol/L. At this substrate concentration the activity 
increased linearly with incubation times up to 90min and the pH optimum was 5.2 (data 
not illustrated). 
Stability ofchitotriosidase: EDTA and heparin plasma, stored for up to 8 years at - 80~ 
in three different laboratories, as well as serum samples tored for 20 years at -20~ were 
used. The effect of anticoagulant, storage, and freeze-thawing on chitotriosidase activity 
was tested. Heparin and EDTA plasma samples from 82 blood donors did not show 
significantly different activities. Likewise, heparin plasma nd serum from 20 :individuals 
showed the same activity. Ten cycles of freezing at - 80~ and thawing had no effect on 
the chitotriosidase activity in plasma or serum. Recently obtained plasma samples from 
blood donors (84 male, 84 female) aged 21-61 years were divided into four age groups of 
10 years (21 persons/group) and matched to serum samples that had been stored for 20 
years a t -20~ (21-30 persons/group). Chitotriosidase in the matched groups did not 
differ significantly. The mean activity in 168 plasma samples did not differ significantly 
from the mean of 32 plasma samples from blood donors that had been stored for 7 years 
at -80~ (4 persons/group). These results indicate that chitotriosidase is a very stable 
enzyme, allowing direct comparison of plasma and serum samples that have been stored 
under widely different conditions. Freeze drying of plasma had no effect on chitotriosidase 
activity and storage of the dried plasma for 3 weeks at room temperature l d to 15% loss 
of enzyme activity. 
Effect of age and sex on chitotriosidase activity: Age-matched samples from 86 male 
and 88 female blood donors (aged 21-65 years) were compared. Chitotriosidase activity 
did not differ significantly. Linear regression analysis of the data, however, showed a clear 
effect of age on chitotriosidase activity (p < 0.003): the activity increased with age. Since 
most of our patients are under 20 years of age, we could not use the blood donors as 
reference group. 
J. lnher. Metab. Dis. 18 (1995) 
Chitotriosidase in lysosomal storage disorders 7 ! 9 
200 t " " " 
g 9 
160 t 
(., 9 9 
>,  120-~ " " 9 . .  
> 
0 - I e ~ 9 9 
~ 80 2 " 9 . , "  " " 9 9 9 9 eee 9 
(~I 9 9 9 
0 " . 8~, . , 9 
"~ " I : . . "  , o  I ,, "% 
oo . " i : : : ' . , i : "  " " 40 , . I , : "ii'" "'"" 9 -- : : ,  9 . . ! . . . . . .  
~.~ ~ ~e * e  9  9 ee e- ee : .ee  e|eeleeI  9 9 
.,'. . .q l , . , ' | l : .8I .  ' %:" .  . . .  ..l 
9 ~I I  I oOeo 9 I I l i ' o  9 ee l  9  9 
v A 9 = . .e_  - ~ = ==1 = ~, ee e,m 9 9 
20 40 ;o 8o 
Age (years) 
Figure 1 Chitotriosidase activity in serum or plasma from 385 control individuals in the age range 
0-81 years 
Table 1 Plasma chitotriosidase activities and deficiencies in controls and Gaucher patients 
Control activity a Deficiency 
Blood donors, male age 21-65 years (n=86) 4-157 0.2-2.2 (n=5) 
Blood donors, female age 22-64 years (n=88) 6-142 0.1 - 1.8 (n=4) 
Controls age 0-81 years (n= 385) 4-195 0.3-1.9 (n=24) 
Gaucher type I (n=5047 1980-69900 0-1.7 (n=30) 
"Range; activities expressed asnmol/h per ml plasma 
%amples collected during a worldwide collaborative study of laboratory 5, hence the high number 
Reference values of  chitotriosidase activity in the general population: Chitotriosidase 
was determined in 26 plasma samples from cord blood and in 359 samples out of about 
5000 sera, which were collected uring an epidemiological survey in a Dutch town. The 
ages ranged between 3 and 81 years (163 women and 186 men; Figure 1 and Table 1). 
After logarithmic transformation, the chitotriosidase values were approximately normally 
distributed. Linear regression analysis showed an age-dependent increase of chito- 
triosidase activity (p<0.001). 
The variation of activity was analysed statistically and chitotriosidase activities for 
which the absolute difference from the mean, after correction for age, was greater than twice 
the standard eviation were regarded as outliers. Using these criteria, 24 persons (6.2%) 
had very low chitotriosidase activities between 0.3 and 1.9 (outliers with chitotriosidase 
deficiency). Among Gaucher patients a similar percentage of deficient individuals was 
found (5.9%; Table 1). The presence of a diffusible inhibitor of chitotriosidase in deficient 
individuals was ruled out by mixing normal and deficient samples. These observations 
indicated heterogeneity in the general population and that about 6% has a chitotriosidase 
deficiency. Only 3 samples (0.8%; Figure 1) had chitotriosidase activities which were 'too 
high' (outliers with very high activity); the reference nzyme a-mannosidase was not 
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Table 2 Plasma ehitotrlosidase activity in 24 lysosomal disorders a 
Yufeng Guo et aL 
Plasma chitotriosidase activity 
Elevated activity 
Disease Abnormal~total (nmol/h per ml) 
Aspartyl glucosaminuria 0/3 
Fabry 0/8 
Gaucher type p,b 20/21 5580-- 51 800 
Glycogen storage disease II 2/8 360; 420 
GM 1-gangliosidosis b 7/13 380; 720-1420 
GM2-gangliosidosis 0/11 
Krabbe disease b 7/11 610-1670 
ct-Mannosidosis 1/3 300 
fl-Mannosidosis 0/2 
Metachromatic leukodystrophy 1/29 550 
Mucopolysaccharidoses 2/63 600; 400 
(I; II; IIIA; B, C; IVA, B) 
Mucolipidosis II/III 0/3 
a-NAGA deficiency 0/2 
Niemann-Pick A/B b 13/15 250; 602-2800 
Niemann-Pick C b 6/11 263; 304-940 
Sialic acid storage disorders 0/1 
Sialidosis 0/1 
Total 58/205 (28%) 
aThe patients in this table were diagnosed in the authors' laboratories (Rotterdam, Nijmegen and Leiden) and 
reflect he relative frequencies ofthe Various diseases. The number of Gaucher patients i therefore different 
from the high number in Table 1 
bDiseases where majority of patients have levated chitotriosidase activity 
elevated in these samples. In the following studies chitotriosidase activity was regarded as 
elevated if it was higher than the highest reference value (i.e. > 195 nmol/h per ml). 
Chitotriosidase activity in leukocytes and fibroblasts: Leukocytes and cultured fibro- 
blasts were available from two individuals with a chitotriosidase deficiency in plasma. The 
activity in leukocytes was also deficient (0.0 and 0.2nmol/h per mg; control range 110- 
280, n--8) whereas the fibroblasts had normal chitotriosidase activity (3.4 and 4.1 nmol/h 
per mg; control range 3.2-14, n = 11). This indicates identity of the plasma and leukocyte 
chitotriosidase and non-identity of the plasma and fibroblast chitotriosidase. 
Chitotriosidase activity in inherited metabolic disorders: Chitotriosidase activity in 
plasma samples from 23 different lysosomal storage disorders was determined and 
considered elevated if it was greater than the highest reference value (195 nmol/h per ml; 
Figure 1). In 10 diseases other than Gaucher disease, slight to moderate levations of 
chitotriosidase activity were observed (Table 2). In 4 of these diseases, all sphingo- 
lipidoses, the majority of the patients had elevated activity. In one Niemann-Pick type A 
patient, chitotriosidase activity was followed over a period of 3 months. At the time of 
diagnosis (3 months of age) chitotriosidase was not elevated ( l l8nmol/h per ml); 1.5 
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Table 3 Plasma chitotriosidase activity in other metabolic.and infectious disorders 
Plasma chitotriosidase activity 
Elevated activity 
Disease Abnormal~total (nmol/h per ml) 
Adrenoleukodystrophy 
Canavan disease 
Carbohydrate-deficient glycoprotein syndrome 
Chondrodysplasia punctata 
LCAD deficiency 
Fructose- 1,6-bisphosphatase deficiency 
Glutaric acidaemia I 
Galactosaemia 
Glycogen storage disease III 
Glycogen storage disease IV 
Glycogen storage disease V
Glycogen storage disease VI 
Glycogen storage disease VIII 
G6PD deficiency 
Ichthyosis, X-linked 
Lesch-Nyhan syndrome 
Molybdenum cofactor deficiency 
Propionic acidaemia 
Pyruvate carboxylase d ficiency 
Zellweger syndrome 
Infectious diseases with hepatomegaly 
0/1 
0/1 
0/3 
0/2 
0/1 
0/2 
0/3 
0/4 
0/3 
0/1 
0/2 
0/2 
0/5 
0/1 
1/6 
0/3 
0/1 
0/4 
0/1 
0/1 
0/12 
Total 1/45 
211 
months later it had risen to 278 units and at 6 months of age it was strongly elevated (772 
units). 
As a reference, samples from patients with 21 different non-lysosomal diseases were 
examined; only one patient had marginally elevated activity (Table 3). Infectious diseases 
with hepatomegaly did not lead to elevated chitotriosidase activity (Table 3). 
Chitotriosidase activity in undiagnosed patients suspected of a lysosomal disorder: 
Plasma from patients referred for enzyme analysis for lysosomal disorders but remaining 
undiagnosed was also examined. In 16 out of 486 patients, chitotriosidase was elevated 
(range 350-1570 units, patients aged 1-70 years). 
DISCUSSION 
The physiological role of chitotriosidase is not yet known. Since it is secreted by activated 
macrophages (Hollak et al 1994), a role as chitinase in the defence against chitin- 
containing pathogens seems likely. It is remarkable that about 6% of the population, healthy 
persons and patients alike, have a chitotriosidase d ficiency. This is most clearly illustrated 
by Gaucher type I patients, who have greater than 100-fold elevated activities of chito- 
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triosidase, xcept about 6% who also have a complete chitotriosidase d ficiency. Limited 
family data suggest that this is an autosomal recessive trait. The percentage ofdeficiencies 
in our reference group (559 persons) appeared to decrease with increasing age. The Mann 
-Whitney test indicated that this difference was not significant. Whether chitotriosidase 
deficiency predisposes for certain infectious diseases is presently under investigation. 
Chitotriosidase activity was considered elevated if it was greater than the highest value 
(195 nmol/h per ml) of 559 reference samples. We have included the three values which 
statistically were considered to be outliers, in order to avoid overlap between patients and 
controls. Among 21 different lysosomal disorders, only Gaucher type I disease is associated 
with very marked elevations of chitotriosidase activity in plasma (100-5000-fold). This 
elevation does not correlate with the well-known elevation of acid phosphatase activity in 
Gaucher disease (Hollak et al 1994). In 10 other lysosomal disorders, small to moderate 
increases of chitotriosidase activity were found. In 4 of these diseases more than two-thirds 
of the patients showed elevations. These 4 diseases and Gaucher disease are sphingolipidoses, 
which suggests that certain, but not all, glycosphingolipids may be able to stimulate 
macrophages to produce chitotriosidase. Limited data (one Niemarm-Pick type A patient) 
suggest that chitotriosidase gradually increases with age, or with severity of the disease. 
Chitotriosidase activity was not elevated significantly in plasma from 20 different non- 
lysosomal enzymopathies or in plasma from patients with infectious diseases with hepato- 
megaly. On the other hand, elevated activities were found in as many as 3% (16/486) of 
undiagnosed patients creened for a lysosomal disorder. It is unlikely that all these patients 
would still have undetected lysosomal disorders. However, our results suggest that these 
patients hould be re-evaluated with special attention for lysosomal disorders. We have 
been unable to correlate levated chitotriosidase activity with specific clinical signs and 
symptoms of these undiagnosed patients. The four highest had encephalopathy with 
perivasculitis of the retina combined with multifocal hypodensities of the white matter, 
limb-girdle dystrophy, organic psychotic syndrome or mental retardation without 
organomegaly and brain abnormalities on MRI. 
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